EA202090176A1 - COMPOSITIONS AND METHODS OF APPLICATION 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-IL) -1-OXOISOINDOLIN-5-IL) METHYL) -2,2-DIFLUOROCETAMAMIDE - Google Patents
COMPOSITIONS AND METHODS OF APPLICATION 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-IL) -1-OXOISOINDOLIN-5-IL) METHYL) -2,2-DIFLUOROCETAMAMIDEInfo
- Publication number
- EA202090176A1 EA202090176A1 EA202090176A EA202090176A EA202090176A1 EA 202090176 A1 EA202090176 A1 EA 202090176A1 EA 202090176 A EA202090176 A EA 202090176A EA 202090176 A EA202090176 A EA 202090176A EA 202090176 A1 EA202090176 A1 EA 202090176A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dioxopiperidin
- oxoisoindolin
- chlorophenyl
- methyl
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
В данном изобретении предложены составы и способы применения 2-(4-хлорфенил)-N-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида, или его стереоизомера, или смеси стереоизомеров, фармацевтически приемлемой соли, таутомера, пролекарства, сольвата, гидрата, сокристалла, клатрата или полиморфа.The present invention provides compositions and methods for using 2- (4-chlorophenyl) -N - ((2- (2,6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide or a stereoisomer thereof, or a mixture of stereoisomers, a pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, cocrystal, clathrate or polymorph.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862673064P | 2018-05-17 | 2018-05-17 | |
PCT/US2018/040286 WO2019006299A1 (en) | 2017-06-30 | 2018-06-29 | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-doxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202090176A1 true EA202090176A1 (en) | 2020-05-06 |
Family
ID=70847682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202090176A EA202090176A1 (en) | 2018-05-17 | 2018-06-29 | COMPOSITIONS AND METHODS OF APPLICATION 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-IL) -1-OXOISOINDOLIN-5-IL) METHYL) -2,2-DIFLUOROCETAMAMIDE |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA202090176A1 (en) |
-
2018
- 2018-06-29 EA EA202090176A patent/EA202090176A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001410A (en) | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6- doxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide. | |
MX2023000085A (en) | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USING THEM. | |
UY38297A (en) | COMPOSITIONS DERIVED FROM 3- (5-HYDROXY-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA, COMPOSITIONS, METHODS AND USES OF THE SAME | |
EA201891578A1 (en) | COMPOSITIONS OF 2- (4-CHLOROPHENIL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-IL) -1-OXYOISOINDOLIN-5-IL) METHYL-2,2-DIPHTORACETAMIDE | |
EA202191833A1 (en) | COMPOSITIONS AND METHODS OF APPLICATION 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE | |
AR108711A1 (en) | FXR MODULATING COMPOUNDS (NR1H4) | |
NZ766284A (en) | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists | |
EA202192029A1 (en) | SUBSTITUTED DERIVATIVES OF 3- (1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE AND VARIANTS OF THEIR APPLICATION | |
EA202192019A1 (en) | DERIVATIVES OF 3- (1-OXO-5- (PIPERIDIN-4-YL) ISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE AND ROUTES OF THEIR APPLICATION | |
EA202091500A1 (en) | Pyrazole N-Bonded Carbamoylcyclohexyl Acids as LPA Antagonists | |
TN2018000130A1 (en) | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
JOP20200059A1 (en) | Bisamide sarcomere activating compounds and uses thereof | |
EA202190681A1 (en) | DIMETHYLAMINOAZETIDINE AMIDES AS JAK INHIBITORS | |
EA202091893A1 (en) | NEW CRYSTALLINE FORMS | |
CY1121746T1 (en) | TETRAZOLONE-DIHYDROPYRIDINONE SUBSTITUTED MGAT2 INHIBITORS | |
BR112018075206A2 (en) | hematologic malignancy treatment with 2- (4-chlorophenyl) -n - ((2- (2,6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide | |
EA202190686A1 (en) | 5-7-MEMBER HETEROCYCLIC AMIDES AS JAK INHIBITORS | |
ECSP18023544A (en) | FORMULATIONS OF 3- (5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-IL) -PIPERIDIN-2,6-DIONA | |
WO2021026479A9 (en) | Small molecule inhibitors of s1p2 receptor and uses thereof | |
EA202090176A1 (en) | COMPOSITIONS AND METHODS OF APPLICATION 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-IL) -1-OXOISOINDOLIN-5-IL) METHYL) -2,2-DIFLUOROCETAMAMIDE | |
EA202090261A1 (en) | ANTIPROLIFERATIVE COMPOUNDS AND WAYS OF THEIR APPLICATION | |
EA202091472A1 (en) | TRIAZOL-AZINES OF CYCLOHEXYLIC ACID AS LPA ANTAGONISTS | |
EA202090241A1 (en) | NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS | |
EA202090930A1 (en) | COMPOUNDS SUITABLE FOR CDK7 INHIBITION |